Simplify Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Simplify Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-245,000	Closed	-$777K	–	117
2023 Q3	$777K	Hold	245,000	–	–	0.09%	81
2023 Q2	$1.22M	Hold	245,000	–	–	0.16%	71
2023 Q1	$1.21M	Buy	+245,000	New	+$1.57M	0.17%	57

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Simplify Asset Management's ALLO Position: Q4 2023 in Review

Simplify Asset Management sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 245,000 shares — an estimated $777K sold.

Simplify Asset Management first reported a position in ALLO in Q1 2023 and held it in 3 quarters. The position peaked at $1.22M in Q2 2023. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

Simplify Asset Management reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
Simplify Asset Management sold 245,000 Allogene Therapeutics shares in Q4 2023, an estimated $777K.
Simplify Asset Management first reported a position in Allogene Therapeutics in Q1 2023 and held it in 3 quarters.
Simplify Asset Management's Allogene Therapeutics position peaked at $1.22M in Q2 2023.
170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on Simplify Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.